25p 2.3 9.9%
Last Trade - 09/04/21
| Market Cap | £160.2m |
| Enterprise Value | £123.9m |
| Revenue | £81.8m |
| Position in Universe | 901st / 1817 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 30th Jun | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 43.2 | 48.5 | 64.1 | 68.3 | 73.7 | 78.2 | 83.0 | 88.1 | +12.6% | ||
| -86.0 | +102.3 | |||||||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Allergy Therapeutics Plc is a pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum-free products. The Company's segments are Central Europe, which includes segments, such as Germany, Australia, Switzerland and the Netherlands; Southern Europe, which includes Italy and Spain; the United Kingdom, and Rest of World. The Company provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy. The Company's products include Pollinex Trees, Pollinex Grasses+Rye, Skin Prick Testing and diagnostic products. Its vaccines trade under various brand names, such as Pollinex Quattro, Polligoid and TA Graser Top. It uses specialized systems to process the Tyrosine to form a suspension microcrystalline tyrosine (MCT) that is combined with some of its subcutaneous injected therapies.
| Last Annual | June 30th, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | June 1, 2004 |
| Public Since | October 11, 2004 |
| No. of Shareholders: | n/a |
| No. of Employees: | 571 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | FTSE Aim All Share , |
| Exchange | London Stock Exchange (AIM) |
| Shares in Issue | 640,940,533 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | Dominion Way, WORTHING, BN14 8SA, United Kingdom |
| Web | http://www.allergytherapeutics.com/ |
| Phone | +44 1903 844700 |
| Contact | () |
| Auditors | Grant Thornton UK LLP |
As of 09/04/21, shares in Allergy Therapeutics are trading at 25p, giving the company a market capitalisation of £160.2m. This share price information is delayed by 15 minutes.
Shares in Allergy Therapeutics are currently trading at 25p and the price has moved by 0.144k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Allergy Therapeutics price has moved by 97.05% over the past year.
Of the analysts with advisory recommendations for Allergy Therapeutics, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Allergy Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Allergy Therapeutics is scheduled to issue upcoming financial results on the following dates:
Allergy Therapeutics does not currently pay a dividend.
Allergy Therapeutics does not currently pay a dividend.
Allergy Therapeutics does not currently pay a dividend.
To buy shares in Allergy Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Allergy Therapeutics are currently trading at 25p, giving the company a market capitalisation of £160.2m.
Here are the trading details for Allergy Therapeutics:
Based on an overall assessment of its quality, value and momentum, Allergy Therapeutics is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Allergy Therapeutics are currently priced at 25p. At that level they are trading at 64.24% discount to the analyst consensus target price of 69.91.
Analysts covering Allergy Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -0.00808 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Allergy Therapeutics. Over the past six months, the relative strength of its shares against the market has been 23.47%. At the current price of 25p, shares in Allergy Therapeutics are trading at 49.02% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Allergy Therapeutics PE ratio based on its reported earnings over the past 12 months is 20.41. The shares are currently trading at 25p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Allergy Therapeutics's management team is headed by:
Here are the top five shareholders of Allergy Therapeutics based on the size of their shareholding:
